left-arrow right-arrow pinterest facebook google_plus linkedin

NRG GY005

Status:

Recruiting | Phase III

Official Title:

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Study Purpose:

To confirm the effectiveness of the combination of Cediranib and Olaparib to the standard chemotherapy.

Interventions:


Group 1: Standard of care chemotherapy

Group 2: Combination of oral medications, Cediranib and Olaparib taken daily

Group 3:  Cediranib taken daily

Key Participation Requirements:

Gender:

Female

Age:

19 years and older

Diagnosis:

Recurrent ovarian, primary peritoneal, or fallopian tube cancer

Marker Status:

BRCA testing through Myriad

Eligibility:

No more than three prior treatments.

May not have previously received a PARP-inhibitor.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

NRG GY005

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!